All News
ANA Pollution (2.06.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
Read Article
FDA vs. Amgen: At Odds Over Avacopan
MedPage Today
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market.
Read Article
RT @Gibson_RheumPAC
Nearly 50% of U.S. adults may meet criteria for obesity by 2030.
For rheumatologists, it directly impacts disease activity, outcomes, and treatment response. #RNL26 https://t.co/cpy4LBBPHc
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_RheumPAC
Osteoarthritis affects 600 million people worldwide—yet we still have no approved disease-modifying therapies.
A powerful opening to this talk on why OA drug development keeps missing the mark. https://t.co/wBUN3lux6X
Dr. John Cush RheumNow ( View Tweet)
Semaglutide ameliorates osteoarthritis via wt loss-independent mechanism. GLP-1R agonist exhibits OA chondroprotective effects in a mouse model of obesity by changing chondrocyte metabolism from glycolysis to oxidative phosphorylation via the “GLP-1R-AMPK-PFKFB3” axis.
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/mJSmMakSBM
Dr. John Cush RheumNow ( View Tweet)
Rheum Cases & Guidelines
https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/TCsDfeQjZC
Dr. John Cush RheumNow ( View Tweet)
FDA vs. Amgen: At Odds Over Avacopan
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market. https://t.co/v5AYm6r53W
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Recent Government Funding
The American College of Rheumatology (ACR) praised the recent Congressional CY 26 funding package, highlighting its provisions to extend Medicare telehealth payment flexibilities, enhance transparency in pharmacy benefit management, and https://t.co/gr3X7RRGLN
Dr. John Cush RheumNow ( View Tweet)
Air pollution ups ANA+: Ontariio Canadi study of 3548 serum samples (2010-13) corrlated particulate matter (PM2.5) w/ serologies. Highest vs lowest quartile PM2.5 showed higher risk of ANA ≥1:640 (OR 1.46) & ≥1:1280 (OR 1.54). Pollution has systemic immune effects! https://t.co/iyC68qh49R
Dr. John Cush RheumNow ( View Tweet)
Study shows half of FL autonomous nurse practitioners practicing outside their scope of practice. FL law allows autonomous NPs in primary care w/ 3K practice hrs. 194/328 NPs working in non-primary care: cosmetics, antiaging, IV hydration, vitamin infusions, hormonal Rx, https://t.co/WMksEb0Uyc
Dr. John Cush RheumNow ( View Tweet)
Always on exams, but I've never seen a case! JAMA Dermatology reviews Multicentric Reticulohistiocytosis - pt w/ multiple nodules on hands & pain in shoulders, elbows, MCPs, IPs. Erythema over face, chest, & back & bead like Perionychial papules. Rx w/ MTX + Pred https://t.co/QgS5VBOB51
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Anca Dinu Askanase, MD, MPH, who has been appointed Chair of the Department of Medicine and Chief of the Division of Rheumatology at Hospital for Special Surgery https://t.co/L5mbFloLpK https://t.co/gsZm9Is159
Dr. John Cush RheumNow ( View Tweet)
Take home points from his presentation. Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/kDFrGi7iXt
Dr. John Cush RheumNow ( View Tweet)
Long term outcomes study of 22 pts w/ adult Stills. 16 (72.7%) completed LTE w/ mean observation 168.9 wks. 3/22 had serious adverse events, Tx efficacy ACR70=68% and 95% reduced in glucocorticoid doses w/ 41% in GC-free remission https://t.co/h0MvDLWGhD https://t.co/HDIKF7VMwA
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live Preview (1.30.2026)
Top 5 reasons to attend RheumNow Live 2026:
It's cold and far, but you can be there virtually, online
Full access to handouts, slides & downloads, and all session recordings
Saturday concert with Colin Boyd
Dr. Rohit Aggarwal does TWO STEP
Dr. John Cush RheumNow ( View Tweet)
Aortitis in Giant Cell Arteritis Treated with Tocilizumab
The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis (GCA) with aortitis, comparing the efficacy of intravenous (IV) vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating https://t.co/GPt7sTzbpH
Dr. John Cush RheumNow ( View Tweet)
TOPKAT Trial: Partial vs Total Knee Replacement
Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit https://t.co/SsTXAqs4Xr
Dr. John Cush RheumNow ( View Tweet)
Air pollution ups ANA+: Ontariio Canadi study of 3548 serum samples (2010-13) corrlated particulate matter (PM2.5) w/ serologies. Highest vs lowest quartile PM2.5 showed higher risk of ANA ≥1:640 (OR 1.46) & ≥1:1280 (OR 1.54). Pollution has systemic immune effects! https://t.co/fJrhypNE2A
Dr. John Cush RheumNow ( View Tweet)
